ABT · News · 20260819N
Guidance / Outlook
ABBOTT LABORATORIES · 2026-08-19 · Importance 57 · Surprise 76 · In source text
Abbott raised its full-year 2026 earnings outlook after second-quarter results exceeded expectations. The revised outlook is supported by demand for cancer diagnostics and Medical Devices, as well as the Exact Sciences acquisition. Analysts cited a projected 10.4% earnings compound annual growth rate over six years, while regulatory challenges and Nutrition risks remain considerations.
Key facts
- Abbott's Exact Sciences acquisition is cited as strengthening its long-term growth runway and contributing to raised EPS outlook and a projected 10.4% CAGR over the next six years. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Abbott's Exact Sciences acquisition is cited as strengthening its long-term growth runway and contributing to raised EPS outlook and a… |